{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T15:13:29Z","timestamp":1780758809905,"version":"3.54.1"},"reference-count":67,"publisher":"Impact Journals, LLC","issue":"37","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2017,9,5]]},"DOI":"10.18632\/oncotarget.19117","type":"journal-article","created":{"date-parts":[[2017,7,10]],"date-time":"2017-07-10T15:10:55Z","timestamp":1499699455000},"page":"62545-62560","source":"Crossref","is-referenced-by-count":36,"title":["Antihypertensive drug use and breast cancer risk: a meta-analysis of observational studies"],"prefix":"10.18632","volume":"8","author":[{"given":"Haibo","family":"Ni","sequence":"first","affiliation":[{"name":"Department of Neurosurgery, The First People\u2019s Hospital of Zhangjiagang City, Suzhou, Jiangsu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qin","family":"Rui","sequence":"additional","affiliation":[{"name":"Department of Laboratory, The First People\u2019s Hospital of Zhangjiagang City, Suzhou, Jiangsu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojue","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Laboratory, The First People\u2019s Hospital of Zhangjiagang City, Suzhou, Jiangsu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenquan","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Gao","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, The First People\u2019s Hospital of Zhangjiagang City, Suzhou, Jiangsu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huixiang","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, The First People\u2019s Hospital of Zhangjiagang City, Suzhou, Jiangsu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7892","published-online":{"date-parts":[[2017,7,10]]},"reference":[{"key":"1","unstructured":"World Health Organization. A global brief on hypertension: silent killer, global public health crisis. 2013. Available at: http:\/\/ish-world.com\/downloads\/pdf\/global_brief_hyperten-sion.pdf."},{"key":"2","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1001\/jamainternmed.2013.9071","article-title":"Use of antihypertensive medications and breast cancer risk among women aged 55 to 74 years","volume":"173","author":"Malone","year":"2013","journal-title":"JAMA Intern Med"},{"key":"3","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.molmed.2011.01.009","article-title":"Can antihypertensive drugs increase the risk of cancer?","volume":"17","author":"Alriyami","year":"2011","journal-title":"Trends Mol Med"},{"key":"4","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1038\/sj.bjc.6602490","article-title":"A cohort study of antihypertensive treatments and risk of renal cell cancer","volume":"92","author":"Friis","year":"2005","journal-title":"Br J Cancer"},{"key":"5","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1038\/sj.bjc.6603000","article-title":"The association between antihypertensive drugs and glioma","volume":"94","author":"Stricker","year":"2006","journal-title":"Br J Cancer"},{"key":"6","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1002\/ijc.30066","article-title":"Hypertension, use of antihypertensive medications, and risk of epithelial ovarian cancer","volume":"139","author":"Tworoger","year":"2016","journal-title":"Int J Cancer"},{"key":"7","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21332","article-title":"Cancer statistics, 2016","volume":"66","author":"Jemal","year":"2016","journal-title":"CA Cancer J Clin"},{"key":"8","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/S0140-6736(74)93259-0","article-title":"Reserpine use in relation to breast cancer","volume":"304","author":"Turunen","year":"1974","journal-title":"Lancet"},{"key":"9","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1097\/HJH.0000000000000813","article-title":"Antihypertensive agents and the risk of breast cancer in women aged 55 years and older: a nested case-control study","volume":"34","author":"Lai","year":"2016","journal-title":"J Hypertens"},{"key":"10","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1016\/j.canep.2013.10.004","article-title":"Spironolactone use and the risk of breast and gynecologic cancers","volume":"37","author":"Melbye","year":"2013","journal-title":"Cancer Epidemiol"},{"key":"11","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1038\/sj.jhh.1002075","article-title":"Hypertension, diuretics and breast cancer risk","volume":"20","author":"Anton-Culver","year":"2006","journal-title":"J Hum Hypertens"},{"key":"12","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1002\/cncr.11663","article-title":"Relation between use of antihypertensive medications and risk of breast carcinoma among women ages 65-79 years","volume":"98","author":"Daling","year":"2003","journal-title":"Cancer"},{"key":"13","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/S0140-6736(96)04277-8","article-title":"Calcium-channel blockade and incidence of cancer in aged populations","volume":"348","author":"Havlik","year":"1996","journal-title":"Lancet"},{"key":"14","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1001\/jama.279.13.1000","article-title":"Calcium channel blockers and the risk of cancer","volume":"279","author":"Shapiro","year":"1998","journal-title":"JAMA"},{"key":"15","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1002\/pds.910","article-title":"Breast cancer incidence and use of antihypertensive medication in women","volume":"13","author":"Garcia Rodriguez","year":"2004","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"16","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s10549-005-9091-x","article-title":"A cohort study of antihypertensive medication use and breast cancer among Danish women","volume":"97","author":"Friis","year":"2006","journal-title":"Breast Cancer Res Treat"},{"key":"17","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1007\/s10654-007-9135-0","article-title":"Medication use and the risk of breast cancer","volume":"22","author":"Mirick","year":"2007","journal-title":"Eur J Epidemiol"},{"key":"18","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1002\/pds.1656","article-title":"Long-term use of antihypertensive drugs and risk of cancer","volume":"17","author":"Suissa","year":"2008","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"19","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1038\/jhh.2008.131","article-title":"Diuretic use and the risk of breast cancer","volume":"23","author":"Rosenberg","year":"2009","journal-title":"J Hum Hypertens"},{"key":"20","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1007\/s10552-010-9590-x","article-title":"Hypertension, antihypertensive medication use, and breast cancer risk in the California teachers study cohort","volume":"21","author":"Anton-Culver","year":"2010","journal-title":"Cancer Causes Control"},{"key":"21","doi-asserted-by":"crossref","first-page":"e4447","DOI":"10.1136\/bmj.e4447","article-title":"Spironolactone and risk of incident breast cancer in women older than 55 years: retrospective, matched cohort study","volume":"345","author":"Wei","year":"2012","journal-title":"BMJ"},{"key":"22","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s10552-012-0122-8","article-title":"Use of antihypertensive medications and breast cancer risk","volume":"24","author":"Li","year":"2013","journal-title":"Cancer Causes Control"},{"key":"23","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/s10549-015-3311-9","article-title":"Antihypertensive medication use and incident breast cancer in women","volume":"150","author":"Schernhammer","year":"2015","journal-title":"Breast Cancer Res Treat"},{"key":"24","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1097\/EDE.0000000000000483","article-title":"Use of calcium channel blockers and risk of breast cancer: a population-based cohort study","volume":"27","author":"Bouganim","year":"2016","journal-title":"Epidemiology"},{"key":"25","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1002\/cncr.23215","article-title":"Renin-angiotensin system inhibitors, angiotensin I-converting enzyme gene insertion\/deletion polymorphism, and cancer: The Rotterdam study","volume":"112","author":"Stricker","year":"2008","journal-title":"Cancer"},{"key":"26","doi-asserted-by":"crossref","first-page":"e50893","DOI":"10.1371\/journal.pone.0050893","article-title":"Long-term use of angiotensin receptor blockers and the risk of cancer","volume":"7","author":"Suissa","year":"2012","journal-title":"PLoS One"},{"key":"27","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1111\/j.1365-2125.2012.04170.x","article-title":"Long term use of drugs affecting the renin-angiotensin system and the risk of cancer: a population-based case-control study","volume":"74","author":"Bjerrum","year":"2012","journal-title":"Br J Clin Pharmacol"},{"key":"28","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1001\/jama.283.15.2008","article-title":"Meta-analysis of observational studies in epidemiology: a proposal for reporting","volume":"283","author":"Thacker","year":"2000","journal-title":"JAMA"},{"key":"29","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Altman","year":"2003","journal-title":"BMJ"},{"key":"30","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.2307\/2533446","article-title":"Operating characteristics of a rank correlation test for publication bias","volume":"50","author":"Mazumdar","year":"1994","journal-title":"Biometrics"},{"key":"31","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Minder","year":"1997","journal-title":"BMJ"},{"key":"32","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s11906-002-0007-4","article-title":"Carcinogenicity of antihypertensive therapy","volume":"4","author":"Goldbourt","year":"2002","journal-title":"Curr Hypertens Rep"},{"key":"33","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1002\/cncr.11695","article-title":"Breast carcinoma and antihypertensive therapy","volume":"98","author":"Giordano","year":"2003","journal-title":"Cancer"},{"key":"34","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1038\/sj.jhh.1002053","article-title":"Hypertension and breast cancer: an association revisited?","volume":"20","author":"Lip","year":"2006","journal-title":"J Hum Hypertens"},{"key":"35","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1097\/HJH.0b013e328344a7de","article-title":"Effects of telmisartan, irbesartan, valsartan, candesartan, and losartan on cancers in 15 trials enrolling 138,769 individuals","volume":"29","author":"ARB Trialists Collaboration","year":"2011","journal-title":"J Hypertens"},{"key":"36","first-page":"68","article-title":"Beta blockers and breast cancer: Results from a collaborative study","volume":"22","author":"Russo","year":"2013","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"37","first-page":"431","article-title":"The long-term use of calcium channel blockers and the risk of breast cancer","volume":"24","author":"Bouganim","year":"2015","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"38","first-page":"312","article-title":"Long-term use of calcium channel blockers, beta-blockers, angiotensin-receptor blockade and risk of breast cancer in women aged 55 years or older: a nationwide study","volume":"24","author":"Lai","year":"2015","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"39","first-page":"552","article-title":"Breast cancer risk with long-term use of calcium channel blockers or angiotensin-converting enzyme inhibitors among postmenopausal women","volume":"24","author":"Xu","year":"2015","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"40","first-page":"15","article-title":"The long-term use of calcium channel blockers and the risk of breast cancer","volume":"33","author":"Azoulay","year":"2015","journal-title":"J Clin Oncol"},{"key":"41","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1002\/(SICI)1097-0142(19971015)80:8<1438::AID-CNCR11>3.0.CO;2-6","article-title":"Use of calcium channel blockers and breast carcinoma risk in postmenopausal women","volume":"80","author":"Weissfeld","year":"1997","journal-title":"Cancer"},{"key":"42","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1161\/01.HYP.29.5.1091","article-title":"Cancer risk in users of calcium channel blockers","volume":"29","author":"Olsen","year":"1997","journal-title":"Hypertension"},{"key":"43","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1001\/archinte.160.3.349","article-title":"Angiotensin-converting enzyme inhibitors, calcium channel blockers, and breast cancer","volume":"160","author":"Jick","year":"2000","journal-title":"Arch Intern Med"},{"key":"44","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1002\/1097-0142(20000701)89:1<165::AID-CNCR21>3.0.CO;2-G","article-title":"Cancer risk and mortality in users of calcium channel blockers","volume":"89","author":"Baron","year":"2000","journal-title":"Cancer"},{"key":"45","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1002\/1097-0142(20011101)92:9<2462::AID-CNCR1596>3.0.CO;2-L","article-title":"Angiotensin-converting enzyme inhibitors and the risk of cancer: a population-based cohort study in Denmark","volume":"92","author":"Olsen","year":"2001","journal-title":"Cancer"},{"key":"46","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1161\/CIRCULATIONAHA.110.007336","article-title":"Use of angiotensin receptor blockers and the risk of cancer","volume":"123","author":"Hviid","year":"2011","journal-title":"Circulation"},{"key":"47","doi-asserted-by":"crossref","first-page":"e2697","DOI":"10.1136\/bmj.e2697","article-title":"Angiotensin receptor blockers and risk of cancer: cohort study among people receiving antihypertensive drugs in UK General Practice Research Database","volume":"344","author":"Smeeth","year":"2012","journal-title":"BMJ"},{"key":"48","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1016\/j.ijcard.2012.05.096","article-title":"Long-term use of angiotensin II receptor blockers and risk of cancer: a population-based cohort analysis","volume":"167","author":"Chiang","year":"2013","journal-title":"Int J Cardiol"},{"key":"49","doi-asserted-by":"crossref","first-page":"e1097","DOI":"10.1097\/MD.0000000000001097","article-title":"Propranolol reduces cancer risk: a population-based cohort study","volume":"94","author":"Kao","year":"2015","journal-title":"Medicine"},{"key":"50","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s40119-015-0035-1","article-title":"Long-term use of antihypertensive agents and risk of breast cancer: a population-based case-control study","volume":"4","author":"Mou","year":"2015","journal-title":"Cardiol Ther"},{"key":"51","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1158\/1055-9965.EPI-15-0547","article-title":"Use of antihypertensive medications not associated with risk of contralateral breast cancer among women diagnosed with estrogen receptor-positive invasive breast cancer","volume":"24","author":"Li","year":"2015","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"52","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1001\/jama.279.13.1000","article-title":"Calcium channel blockers and the risk of cancer","volume":"279","author":"Shapiro","year":"1998","journal-title":"JAMA"},{"key":"53","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s13058-016-0720-6","article-title":"Long-term use of calcium channel blocking drugs and breast cancer risk in a prospective cohort of US and Puerto Rican women","volume":"18","author":"Taylor","year":"2016","journal-title":"Breast Cancer Res"},{"key":"54","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S1470-2045(10)70260-6","article-title":"Antihypertensive drugs and risk of cancer: network meta-analyses and trial sequential analyses of 324 168 participants from randomised trials","volume":"12","author":"Messerli","year":"2011","journal-title":"Lancet Oncol"},{"key":"55","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1007\/s40264-014-0209-0","article-title":"Association between calcium channel blockers and breast cancer: a meta-analysis of observational studies","volume":"23","author":"He","year":"2014","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"56","doi-asserted-by":"crossref","first-page":"e105801","DOI":"10.1371\/journal.pone.0105801","article-title":"Calcium channel blockers and risk of breast cancer: a meta-analysis of 17 observational studies","volume":"9","author":"Hou","year":"2014","journal-title":"PLoS One"},{"key":"57","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1016\/j.amjcard.2010.11.026","article-title":"Angiotensin II receptor blockers and risk of cancer in patients with systemic hypertension","volume":"107","author":"Leu","year":"2011","journal-title":"Am J Cardiol"},{"key":"58","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/j.thromres.2011.11.047","article-title":"Inhibition of the renin-angiotensin system downregulates tissue factor and vascular endothelial growth factor in human breast carcinoma cells","volume":"129","author":"Lorenzet","year":"2012","journal-title":"Thromb Res"},{"key":"59","first-page":"1893","article-title":"Angiotensin II receptor type 1 blockers suppress the cell proliferation effects of angiotensin II in breast cancer cells by inhibiting AT1R signaling","volume":"27","author":"Ren","year":"2012","journal-title":"Oncol Rep"},{"key":"60","doi-asserted-by":"crossref","first-page":"e35667","DOI":"10.1371\/journal.pone.0035667","article-title":"Angiotensin II facilitates breast cancer cell migration and metastasis","volume":"7","author":"Casarini","year":"2012","journal-title":"PLoS One"},{"key":"61","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1677\/erc.1.01136","article-title":"The role of angiotensin II in the regulation of breast cancer cell adhesion and invasion","volume":"13","author":"Vinson","year":"2006","journal-title":"Endocr Relat Cancer"},{"key":"62","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.canlet.2012.10.006","article-title":"Angiotensin II type 1 receptor antagonists inhibit cell proliferation and angiogenesis in breast cancer","volume":"328","author":"Dong","year":"2013","journal-title":"Cancer Lett"},{"key":"63","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1177\/1758834012439738","article-title":"Beta-adrenergic blocking drugs in breast cancer: a perspective review","volume":"4","author":"Visvanathan","year":"2012","journal-title":"Ther Adv Med Oncol"},{"key":"64","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/s11892-007-0031-5","article-title":"Antihypertensive agents, insulin sensitivity, and new-onset diabetes","volume":"7","author":"Bakris","year":"2007","journal-title":"Curr Diab Rep"},{"key":"65","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1002\/ijc.2910520402","article-title":"Insulin resistance and breast cancer risk","volume":"52","author":"Nooijen","year":"1992","journal-title":"Int J Cancer"},{"key":"66","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1002\/cncr.20023","article-title":"Evaluation of the synergistic effect of insulin resistance and insulin-like growth factors on the risk of breast carcinoma","volume":"100","author":"Zheng","year":"2004","journal-title":"Cancer"},{"key":"67","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1097\/00045391-200205000-00005","article-title":"Confounding by indication in epidemiologic studies of commonly used analgesics","volume":"9","author":"Blot","year":"2002","journal-title":"Am J Ther"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.19117","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,30]],"date-time":"2022-07-30T18:09:58Z","timestamp":1659204598000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.19117"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7,10]]},"references-count":67,"journal-issue":{"issue":"37","published-print":{"date-parts":[[2017,9,5]]}},"alternative-id":["19117","28977968"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.19117","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,7,10]]}}}